+Vote!
Medical News Today (Free subscription) | 04/09/2008
Forest Laboratories, Inc. (NYSE: FRX) and Laboratorios Almirall, S.A. announced results from two global Phase III studies of aclidinium bromide, a novel long-acting inhaled anticholinergic for the treatment of patients with chronic obstructive pulmonary disease (COPD).
+Vote!
Red Orbit (Free subscription) | 04/09/2008
Shares of Forest Laboratories Inc. fell to a seven-year low Wednesday following disappointing results from two late-stage trials of Forest's drug candidate aclidinium bromide.
+Vote!
24/7 Wall St. (Free subscription) | 03/09/2008
Corning (GLW) Revises forecasts down. Falls to $17.04 from 52-week high of $28.07. Forest Laboratories (FRX) Major drug plans go off track. Down to $29.81 from... [[ This is a content summary only. Visit my website for full links, other content, and more! ]]
+Vote!
Market Watch (Free subscription) | 03/09/2008
TEL AVIV (MarketWatch) -- Forest Laboratories Inc., the New York drugmaker, and Laboratorios Almirall SA reported results from two global Phase III studies of aclidinium bromide, a potential treatment for chronic obstructive pulmonary disease. Both studies showed a statistically significant difference versus placebo in the primary endpoint, the companies said. "The studies confirm the bronchodilatory...
1Vote!
Hindu (Free subscription) | 19/08/2008
MUMBAI: Lupin has entered into a multi-year promotion and marketing agreement for the AeroChamber Plus line of products with Forest Laboratories of the U.S. Under the agreement, Lupin Pharmaceuticals of the U.S will use its 50 person sales ...
+Vote!
Red Orbit (Free subscription) | 19/08/2008
MUMBAI, India and BALTIMORE, Aug. 19 /PRNewswire/ -- Lupin Ltd. announced today that the Company has entered into a multi-year promotion and marketing agreement for the AeroChamber Plus(R) line of products with Forest Laboratories, Inc.
+Vote!
Big News Network.com (Free subscription) | 19/08/2008
Mumbai, Aug 19 (IANS) Pharmaceutical major Lupin Laboratories has entered into a promotion and marketing agreement with US-based Forest Laboratories for its Aerochamber line of products, it announced Tuesday.
+Vote!
GuruFocus Updates (Free subscription) | 15/08/2008
While a lot of value investors got hurt with the recent downturn, Bruce Berkowitz did well by owning energy stocks and not owning financials. Now the "Ignore the Crowd" guru is reducing energy holdings and invest heavily into healthcare stocks. These are his buys and sells during the second quarter.
1Vote!
Medical News Today (Free subscription) | 01/08/2008
Forest Laboratories, Inc. (NYSE: FRX) presented positive Phase III data of a once-daily extended-release formulation of Namenda® (memantine HCl) at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD).
+Vote!
Medical News Today (Free subscription) | 31/07/2008
Forest Laboratories, Inc. (NYSE: FRX) presented positive Phase III data of a once-daily extended-release formulation of Namenda(R) (memantine HCl) at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD).
+Vote!
The Earth Times Online Newspaper (Free subscription) | 22/07/2008
NEW YORK (Reuters) - Forest Laboratories Inc reported a 9 percent decline in quarterly profit on Tuesday on higher sales and administrative costs, but results were better than expected and the company forecast fiscal-year earnings ahead of analyst projections.
+Vote!
Reuters (Free subscription) | 22/07/2008
NEW YORK (Reuters) - Forest Laboratories Inc reported a 9 percent decline in quarterly profit on Tuesday on higher sales and administrative costs, but results were better than expected and the company forecast fiscal-year earnings ahead of analyst projections.
+Vote!
Market Watch (Free subscription) | 22/07/2008
NEW YORK (MarketWatch) -- Forest Laboratories Inc. said Tuesday that it earned $242.9 million, or 79 cents a share, in its first quarter, down from $268.2 million, or 83 cents a share, in the year-earlier period. The latest results included a charge of 8 cents a share, related to a terminated co-promotion agreement with Daiichi Sankyo. The New York pharmaceutical company said revenue for the quarter...
+Vote!
Seeking Alpha (Free subscription) | 21/07/2008
Forest Laboratories (FRX) is expected to report Q1 earnings before market open Tuesday, with a conference call scheduled for 10:00 am ET. Guidance Analysts are looking for a profit of 80c on revenue of $978.86M. The consensus is 72c to 87c for EPS, and revenue of $931.58M to $1.01B, according to First Call. The company reported Q4 EPS 90c vs. consensus of 76c and Q4 revenue $990.85M vs. consensus...
